SENTI-401 / Senti Bio - LARVOL DELTA

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance (GlobeNewswire) - "Senti Biosciences, Inc...announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of Gene Circuits for other programs, including solid tumors. The Company does not intend to invest in the clinical development of SENTI-301A, for the treatment of hepatocellular carcinoma (HCC), on its own at this time; however, the Company believes there is significant market opportunity for SENTI-301A, especially in territories within Asia where HCC is more prevalent than in the United States....With SENTI-202, a Logic Gated (OR+NOT) off-the-shelf CAR-NK cell product candidate that is designed to target and eliminate acute myeloid leukemia (AML) cells while sparing the healthy bone marrow, the Company has commenced IND-enabling studies and remains on track to file an IND application in the second half of 2023."

IND • Pipeline update • Acute Myelogenous Leukemia • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

SENTI-401, an Allogeneic Logic-Gated and Multi-Armed CAR-NK Cell Therapy for the Treatment of CEA-Expressing Solid Tumors with Enhanced Selectivity and Efficacy (SITC 2022) - "Similarly, we optimized gene-circuits to confer resistance to the immunosuppressive effects of TGFb; anti-CEA CAR-NK cells armed with TGFb-blocking constructs sustained target-cell killing in the continuous presence of TGFb. Conclusions SENTI-401 incorporates NOT-Gating and Multi-Arming gene-circuits into CAR-NK cells in order to improve the therapeutic window and efficacy of CEA-targeting cell-therapies for the treatment of solid tumors."

Clinical • Hematological Malignancies • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CEACAM5 • IL15 • IL21

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting (GlobeNewswire) - "Senti Biosciences...announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held November 10-12, 2022, in Boston, MA....Abstracts highlight Senti Bio’s continued progress in applying gene circuits to improve the cytotoxicity and persistence of allogeneic CAR-NK cells for the potential treatment of solid tumors."

Preclinical • Oncology • Solid Tumor

Development of Logic Gated CAR-NK cells for the treatment of solid tumors (SITC 2021) - "Conclusions We are developing Logic-Gated CAR-NK cell therapies aimed at reducing on-target off-tumor toxicities, to spare healthy cells in a SA-dependent manner. SENTI-401 will focus on targeting CEA+ CRC tumors with a NOT gate that recognizes the SA VSIG2 in the colon and lungs."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • TNFA

Senti Bio Highlights Colorectal Cancer Preclinical Data from Logic Gated CAR-NK Cell Program at 36th SITC Annual Meeting (GlobeNewswire) - "Senti Bio...announced results from SENTI-401, one of its preclinical stage oncology programs, that aims to more precisely target tumors while sparing healthy cells. The poster presentation, which is on display starting today at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), describes preclinical data from SENTI-401...Preclinical proof-of-concept data suggest that Logic Gated gene circuits can be used in CAR-NK cells to prevent target-mediated toxicity on healthy epithelial tissues."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology